Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 64Terminated 18Withdrawn 6Unknown 6Recruiting 5Active not recruiting 3Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 2Warts 1Neutropenia 1Lymphoma, Non-Hodgkin 1Leukopenia 1Leukemia, Myeloid, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × plerixafor × Clear all
NCT00967785 2026-05-22

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
20 enrolled

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Leukopenia, Neutropenia, Warts

NCT05470491 2026-05-22

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
265 enrolled
Other hematologic neoplasm

Acquired Immunodeficiency Syndrome, Hematologic Neoplasms

NCT06158828 2026-05-05

ABCD-NK

Washington University School of Medicine

Phase 1/2 Recruiting
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT07188090 2025-11-28

HSCT

Thomas Jefferson University

Phase 2 Recruiting
100 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡